Novartis has signed an agreement for the acquisition of all outstanding shares of US-based Avidity Biosciences for $12bn in cash on a fully diluted basis. This represents an enterprise value of close to $11bn at the expected closing date of the deal. Novartis has been proactively...

BioCryst Pharmaceuticals, Inc. announced it will acquire Astria Therapeutics, Inc., a biopharma company specializing in allergic and immunologic disease therapies, in a cash-and-stock deal valued at $13.00 per share, or approximately $700 million in enterprise value. Following...

Akero Therapeutics, Inc. a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that it has entered into a definitive agreement to be acquired by Novo Nordisk  for up to $5.2...

Genmab and Merus had announced today that they have entered into a transaction agreement pursuant to which Genmab intends to acquire all the shares of Merus, a clinical-stage biotechnology company with its late-stage breakthrough therapy asset petosemtamab, which is in Phase 3...

Roche has signed a definitive merger agreement for the acquisition of clinical-stage biopharmaceutical company 89bio, for a total equity value of around $2.4bn. Under the deal, Roche will initiate a tender offer to purchase all outstanding shares of 89bio common stock at $14.50 per...

Merck, a leading science and technology company, had announced that it has closed the acquisition of SpringWorks Therapeutics, for an enterprise value of $3.4 billion, following regulatory clearances and the fulfillment of other customary closing conditions. The definitive...

AbbVie has signed a definitive agreement to acquire Gilgamesh Pharmaceuticals’ lead investigational candidate, bretisilocin, for up to $1.2bn, including an upfront payment and development milestones. The therapy is undergoing clinical development for patients suffering from...

Kite, a Gilead Company ,  announced that it has entered into a definitive agreement to acquire Interius BioTherapeutics, a privately held biotechnology company developing in vivo CAR therapeutics, for $350 million. This acquisition complements Kite’s expertise in cell...

Sun Pharmaceutical Industries Limited had announced the successful completion of its acquisition of Checkpoint Therapeutics, Inc. an immunotherapy and targeted oncology company. As part of the acquisition, Sun Pharma acquires UNLOXCYTTM, the first and only FDAapproved anti-PD-L1...

Torrent Pharmaceuticals, has signed definitive agreements for the acquisition of a controlling stake in JB Chemicals and Pharmaceuticals (JB Pharma) from global investment firm KKR at an equity valuation of Rs256.89bn ($3bn) on a fully diluted basis. The move is part of...